Background Cancer patients appear to be at a higher risk of complications from coronavirus disease 2019 (COVID-19). Specific data related to lung cancer (LC) patient management, active treatment, and/or recent diagnosis are still very limited. Here, we aimed to investigate the clinical presentation, baseline features, and clinical outcomes of LC patients with COVID-19. Methods A retrospective case study was performed at Centro Hospitalar Universitário de São Joao, a tertiary hospital in the North of Portugal. Data from LC patients diagnosed with COVID-19 were collected during the first 10 months of the COVID-19 pandemic (March 2020–January 2021). Results Twenty-eight patients with active LC were diagnosed with COVID-19, being adenocarcinoma the most common histological type present ( n = 13, 46.4%). Sixteen patients had metastatic stage IV LC (61.5%). Twenty-five patients (89.3%) had relevant comorbidities including hypertension (39.3%) and chronic obstructive pulmonary disease (32.1%). For patients undergoing antineoplastic treatment, the median time from the last chemotherapy administration to COVID-19 diagnosis was of 16 days (interquartile range = 13–41 days). Half of patients were previously on corticosteroid therapy. Twenty patients (71.4%) needed hospitalization, 18 received oxygen therapy (64.3%), 3 (10.7%) of them received high-flow nasal cannula with good tolerability, and 1 (3.6%) needed non-invasive ventilation. Hydroxychloroquine and antibiotics were given to 4 (14.3%) and 12 (42.9%) patients, respectively. Seven patients (25%) died at a median time of 5 days following COVID-19 diagnosis. Conclusion This is one of the first studies reporting the adverse outcomes associated with COVID-19 in LC patients at same time that adds evidence regarding the need to create protocols and guidelines to reduce the infection risk in such patients.
【저자키워드】 COVID-19, Infection, lung cancer, Clinical management, Thoracic oncology, 【초록키워드】 Treatment, coronavirus disease, protocol, Hospitalization, COVID-19 pandemic, hospital, Diagnosis, Comorbidity, Antibiotics, nasal, hypertension, Clinical outcome, adverse outcome, Chemotherapy, Features, management, Patient, COVID-19 diagnosis, Oxygen therapy, Complication, non-invasive ventilation, infection risk, Portugal, patients, pulmonary disease, Evidence, retrospective, administration, interquartile range, Tolerability, higher risk, median time, North, Specific, corticosteroid therapy, Result, collected, died, was performed, were given, reduce, histological, chronic obstructive, baseline, diagnosed with COVID-19, patients with COVID-19, the median, with COVID-19, 【제목키워드】 experience, center,